breast cancer
Conditions
Interventions
Case series:paclitaxel-containing neoadjuvant chemotherapy
Sponsors
Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Women aged 18 to 70 years; 2. Pathologically confirmed invasive breast cancer before neoadjuvant chemotherapy.Patients with stageI-IIIB clinical evaluation and indications of neoadjuvant chemotherapy according to NCCN guidelines; 3. Neoadjuvant chemotherapy including AC-TTACTCATTP (Her2 positive patients can be combined with trastuzumab); 4. In preoperative examination, no evidence of metastasis was found in clinical or imaging studies; 5. Modified radical mastectomy or Breast conserving surgery was performed after neoadjuvant chemotherapy, and postoperative specimens were evaluated using the standard miller-payne (MP) system; 6. Eastern Cooperative Oncology Group(ECOG) Performance Status <=1; 7. Complete clinicopathological data; 8. Signed Informed Consent Form(ICF).
Exclusion criteria
Exclusion criteria: 1. Any prior (ipsilateral or contralateral) history of breast cancer other than lobular carcinoma in situ (LCIS); 2. Any metastasis; 3. Other systemic and local treatments, such as endocrine therapy and radiotherapy, other than those allowed by the program; 4. Other malignant tumors, excluding cured cervical carcinoma in situ, skin basal cell carcinoma; 5. Neoadjuvant chemotherapy was not completed; 6. Incomplete medical records or missing pathological specimens.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pathological remission rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective Response Rate; | — |
Contacts
Public ContactFaliang Xu
Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital
Outcome results
None listed